Klaria Interimreport 1 January–30 June 2022 Q2 2022
Klaria Interimreport 1 January–30 June 2022 Q2 2022
Summary of the interim report
Second quarter of 2022
- Net sales amounted to 0.0 MSEK (0.0 MSEK)
- Other income amounted to 3.7 MSEK (0.0 MSEK)
- R&D costs for the period amounted to 14.7 MSEK (11.5 MSEK)
- Profit after tax amounted to -14.5 MSEK (15.9 MSEK)
- Earnings per share for the quarter amounted to -0.24 SEK (0.31 SEK)
- Cash flow from operating activities amounted to -15.7 MSEK (13.5 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 7.3 MSEK (39.7 MSEK)
- Equity as of June 30 amounted to 57.7 MSEK (110.4 MSEK)
The Period January-June
- Net sales amounted to 0.0 MSEK (0.0 MSEK)
- Other income amounted to 4.1 MSEK (31.3 MSEK)
- R&D costs for the period amounted to 31.8 MSEK (22.9 MSEK)
- Profit after tax amounted to -34.8 MSEK (0.8 MSEK)
- Earnings per share for the quarter amounted to -0.61 SEK (0.02 SEK)
- Cash flow from operating activities amounted to -35.5 MSEK (3.6 MSEK)
- With the support of the issue authorization from the annual general meeting on March 18, 2021, the board decided on a directed share issue of 5,750,000 shares, at a subscription price of 4 SEK per share, corresponding to gross proceeds of 23 MSEK before issue costs.
- Klaria Pharmaceuticals signs an agreement with FluiMed GmbH to develop Sirolimus Alginate film for prevention of organ transplant rejection.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.